La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
***** Acces problem to record *****\

Identifieur interne : 0003580 ( Pmc/Corpus ); précédent : 0003579; suivant : 0003581 ***** probable Xml problem with record *****

Links to Exploration step


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal</title>
<author>
<name sortKey="Mazurek, M" sort="Mazurek, M" uniqKey="Mazurek M" first="M." last="Mazurek">M. Mazurek</name>
</author>
<author>
<name sortKey="Savedia, S" sort="Savedia, S" uniqKey="Savedia S" first="S." last="Savedia">S. Savedia</name>
</author>
<author>
<name sortKey="Bobba, R" sort="Bobba, R" uniqKey="Bobba R" first="R." last="Bobba">R. Bobba</name>
</author>
<author>
<name sortKey="Garside, S" sort="Garside, S" uniqKey="Garside S" first="S." last="Garside">S. Garside</name>
</author>
<author>
<name sortKey="Rosebush, P" sort="Rosebush, P" uniqKey="Rosebush P" first="P." last="Rosebush">P. Rosebush</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">9647315</idno>
<idno type="pmc">2170106</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2170106</idno>
<idno type="RBID">PMC:2170106</idno>
<date when="1998">1998</date>
<idno type="wicri:Area/Pmc/Corpus">000358</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000358</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal</title>
<author>
<name sortKey="Mazurek, M" sort="Mazurek, M" uniqKey="Mazurek M" first="M." last="Mazurek">M. Mazurek</name>
</author>
<author>
<name sortKey="Savedia, S" sort="Savedia, S" uniqKey="Savedia S" first="S." last="Savedia">S. Savedia</name>
</author>
<author>
<name sortKey="Bobba, R" sort="Bobba, R" uniqKey="Bobba R" first="R." last="Bobba">R. Bobba</name>
</author>
<author>
<name sortKey="Garside, S" sort="Garside, S" uniqKey="Garside S" first="S." last="Garside">S. Garside</name>
</author>
<author>
<name sortKey="Rosebush, P" sort="Rosebush, P" uniqKey="Rosebush P" first="P." last="Rosebush">P. Rosebush</name>
</author>
</analytic>
<series>
<title level="j">Journal of Neurology, Neurosurgery, and Psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<idno type="eISSN">1468-330X</idno>
<imprint>
<date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>A 37 year woman developed neuroleptic induced parkinsonism that persisted long after the drug had been discontinued. This prompted a study of the effect of an eight week course of haloperidol (HAL) followed by two week withdrawal, on dopaminergic neurons of the substantia nigra in rats. Animals treated with HAL showed a highly significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons in the substantia nigra, and 20% contraction of the TH stained dendritic arbour. Neuroleptic drug induced downregulation of nigral dopaminergic neurons may help to explain the persistent parkinsonism found in many patients after withdrawal of medication.

</p>
</div>
</front>
</TEI>
<pmc article-type="brief-report">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id>
<journal-title>Journal of Neurology, Neurosurgery, and Psychiatry</journal-title>
<issn pub-type="ppub">0022-3050</issn>
<issn pub-type="epub">1468-330X</issn>
<publisher>
<publisher-name>BMJ Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">9647315</article-id>
<article-id pub-id-type="pmc">2170106</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mazurek</surname>
<given-names>M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Savedia</surname>
<given-names>S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bobba</surname>
<given-names>R.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garside</surname>
<given-names>S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosebush</surname>
<given-names>P.</given-names>
</name>
</contrib>
</contrib-group>
<aff>Department of Medicine (Neurology), McMaster University Medical Centre, Hamilton, Ontario, Canada.</aff>
<pub-date pub-type="ppub">
<month>6</month>
<year>1998</year>
</pub-date>
<volume>64</volume>
<issue>6</issue>
<fpage>799</fpage>
<lpage>801</lpage>
<self-uri xlink:role="pdf" xlink:type="simple" xlink:href="http://jnnp.bmj.com/cgi/reprint/64/6/799.pdf"></self-uri>
<self-uri xlink:role="abstract" xlink:type="simple" xlink:href="http://jnnp.bmj.com/cgi/content/abstract/64/6/799"></self-uri>
<self-uri xlink:role="fulltext" xlink:type="simple" xlink:href="http://jnnp.bmj.com/cgi/content/full/64/6/799"></self-uri>
<abstract>
<p>A 37 year woman developed neuroleptic induced parkinsonism that persisted long after the drug had been discontinued. This prompted a study of the effect of an eight week course of haloperidol (HAL) followed by two week withdrawal, on dopaminergic neurons of the substantia nigra in rats. Animals treated with HAL showed a highly significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons in the substantia nigra, and 20% contraction of the TH stained dendritic arbour. Neuroleptic drug induced downregulation of nigral dopaminergic neurons may help to explain the persistent parkinsonism found in many patients after withdrawal of medication.

</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0003580 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0003580 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     
   |texte=   
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022